1133766-06-9
1133766-06-9 structure
- Name: Onartuzumab
- Chemical Name: Onartuzumab
- CAS Number: 1133766-06-9
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK c-Met/HGFR
- Create Date: 2022-11-10 16:48:46
- Modify Date: 2023-01-23 11:07:38
-
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity[1].
| Name | Onartuzumab |
|---|
| Description | Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Onartuzumab acts specifically by blocking HGF α-chain (but not β-chain) binding to MET[1]. Onartuzumab blocks HGF binding to human c-Met with an inhibitory concentration (IC)50 of 1.8 nM and inhibits the subsequent induction of c-Met auto-phosphorylation and cell proliferation in many cancer cell lines[2]. |
| In Vivo | Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth[3]. Animal Model: Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells[3] Dosage: 30 mg/kg Administration: IP, twice a week for 2 mouth Result: Suppressed tumor growth, but did not affect the mean in vivo human HGF levels. Animal Model: U-87 MG tumor-bearing mice[3] Dosage: 30 mg/kg Administration: IP, once Result: Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression). |
| No Any Chemical & Physical Properties |